Compare Moderna, Inc. (MRNA) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rigetti Computing Inc — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Rigetti Computing Inc trades at $15.43 (market cap $4.74B). The key difference: Moderna, Inc. is far larger — about 5× Rigetti Computing Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | RGTI | |
|---|---|---|
Market Cap | $23.60B | $4.74B |
Sector | Health | Technology |
52-Week High | $81.80 | $56.34 |
52-Week Low | $22.36 | $12.90 |
Enterprise Value | $19.70B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, while showing bearish technical signals with 17 sell indicators versus 5 buy signals. The company maintains strong analyst support with 85.7% buy ratings and a $32.67 consensus price target, despite posting significant losses (-$216.21M net income) and negative margins. Recent news highlights Rigetti's $569M cash position and government contracts supporting its quantum computing roadmap.
RGTI offers substantial upside potential based on analyst targets but carries high risk due to persistent losses and negative profitability metrics. The stock's investment thesis hinges on successful quantum technology commercialization, with current valuation reflecting speculative growth expectations rather than fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
